The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - AstraZeneca; Baxalta; Lilly; Merck; Novartis
Research Funding - Mogam Biotechnology Research Institue (Inst)
 
Myung Ah Lee
No Relationships to Disclose
 
Neesha Dhani
Honoraria - Celgene; Sanofi
Consulting or Advisory Role - Celgene; Incyte
Research Funding - Celgene (Inst)
 
Jon Armstrong
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Riccardo Belli
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Salvatore Ferro
Employment - AstraZeneca
Stock and Other Ownership Interests - Amgen
 
Yong Ben
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca